68-5

97/120

2020; 159: 47-51. doi: 10.1016/j.neures.2020.03. 014. 72) Sekimoto S, Oyama G, Chiba S, Nuermaimaiti M, Sasaki F, Hattori N: Holomedicine; Proof of the Concept of Interactive Three-Dimen‑sional Telemedicine. Mov Disord, 2020; 35: 1719-1720. doi: 10.1002/mds.28249. Epub 2020 Sep 14. PMID: 32926470. 73) Seo JH, Maki T, Miyamoto N, Choi YK, Chung KK, Hamanaka G, Park JH, Mandeville ET, Takase H, Hayakawa K, Lok J, Gelman IH, Kim KW, Lo EH, Arai K: AKAP12 Supports Blood-Brain Barrier Integrity against Isch‑emic Stroke. Int J Mol Sci, 2020; 21: 9078. 74) Shiba-Fukushima K, Inoshita T, Sano O, Iwata H, Ishikawa K, Okano H, Akamatsu W, Imai Y, Hattori N: A Cell-Based High-Throughput Screening Identified Two Compounds that Enhance PINK1-Parkin Signaling, iScience, 2020: 101048. doi.org/10. 1016/j.isci.2020.101048. 75) Shimonaka S, Matsumoto SE, Elahi M, Ishiguro K, Hasegawa M, Hattori N, Motoi Y: Aspar‑agine residue 368 is involved in Alzheimer’s disease tau strain-specific aggregation. J Biol Chem, 2020; 295: 13996-14014. doi:10.1074/jbc.RA120.013271. 76) Shindo A, Tabei KI, Taniguchi A, Nozaki H, Onodera O, Ueda A, Ando Y, Urabe T, Kimura K, Kitagawa K, Hanyu H, Hirano T, Wakita H, Fukuyama H, Kagimura T, Miya‑moto Y, Takegami M, Saito S, Watanabe- Hosomi A, Mizuta I, Ihara M, Mizuno T, Tomimoto H: A nationwide survey and multi‑center registry-based database of cerebral autosomal dominant arteriopathy with subcor‑tical infarcts and leukoencephalopathy in Japan. Front Aging Neurosci, 2020; 12: 216. doi: 10.3389/fnagi.2020.00216. 77) Shiraishi T, Nishikawa N, Mukai Y, Taka‑hashi Y: High levodopa plasma concentration after oral administration predicts levodo‑pa-induced dyskinesia in Parkinson’s disease. Parkinsonism Relat Disord, 2020; 75: 80-84. 78) Shojima Y, Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Nakajima S, Urabe T, Hattori N: Eicosapentaenoic-to- Arachidonic Acid Ratio Predicts Mortality and Recurrent Vascular Events in Ischemic Stroke Patients. J Atheroscler Thromb, 2020; 27: 969-977. doi: 10.5551/jat.52373. ＊ 79) Suda A, Osada T, Ogawa A, Tanaka M, Kamagata K, Aoki S, Hattori N, Konishi S: Functional Organization for Response Inhibi‑tion in the Right Inferior Frontal Cortex of Individual Human Brains. Cereb Cortex, 2020; 30: 6325-6335. doi: 10.1093/cercor/bhaa188. 80) Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Haruyama Y, Kobashi G, Sakakibara R, Shimo Y, Hatano T, Hattori N, Yamamoto T, Hirano S, Yamamoto T, Kuwabara S, Kaji Y, Fujita H, Kadowaki T, Hirata K: Determi‑nants of Low Body Mass Index in Patients with Parkinson’s Disease: A Multicenter Case- Control Study. J Parkinsons Dis, 2020; 10: 213-221. doi: 10.3233/JPD-191741. PubMed PMID: 31868678.＊ 81) Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N: Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord, 2020; 35: 1438-1447. doi:10.1002/mds.28068. 82) Tanaka R, Yamashiro K, Ogawa T, Oyama G, Nishioka K, Umemura A, Shimo Y, Hattori N: The absence of orthostatic heart rate increase is associated with cognitive impairment in Parkinson’s disease. PLoS One, 2020; 15: e0240491. doi: 10.1371/journal.pone.0240491. ＊ 83) Taniguchi D, Takanashi M, Hatano T, Kishi‑kawa S, Shimonaka S, Motoi Y, YaoT, Hattori N: Astrocytic 3-Repeat Tau Pathologies in Progressive Supranuclear Palsy. J Neuro‑pathol Exp Neurol, 2020; 79: 1015-1018. doi: 10.1093/jnen/nlaa073. 84) Taniguchi T, Ando M, Okamoto Y, Yoshimura A, Higuchi Y, Hashiguchi A, Shiga K, Hayashida A, Hatano T, Ishiura H, Mitsui J, Hattori N, Mizuno T, Nakagawa M, Tsuji S, Takashima H: Genetic spectrum of Charcot-Marie-Tooth disease associated with myelin protein zero gene variants in Japan. Clin Genet. 2020 85) Toyama M, Okuma Y, Yamamoto M, Kashi‑hara K, Yoshida K, Saiki H, Maeda T, Tsuboi Y, Takahashi Y, Nakayama T: Non-motor symptoms depending on motor severity in 547